MY172245A - Subcutaneous anti-her2 antibody formulation - Google Patents
Subcutaneous anti-her2 antibody formulationInfo
- Publication number
- MY172245A MY172245A MYPI2014002480A MYPI2014002480A MY172245A MY 172245 A MY172245 A MY 172245A MY PI2014002480 A MYPI2014002480 A MY PI2014002480A MY PI2014002480 A MYPI2014002480 A MY PI2014002480A MY 172245 A MY172245 A MY 172245A
- Authority
- MY
- Malaysia
- Prior art keywords
- her2 antibody
- formulations
- formulation
- stabilizer
- mixture
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 238000009472 formulation Methods 0.000 title abstract 6
- 238000007920 subcutaneous administration Methods 0.000 title 1
- 239000003381 stabilizer Substances 0.000 abstract 3
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract 2
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 229960002087 pertuzumab Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 229960000575 trastuzumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09167025 | 2009-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY172245A true MY172245A (en) | 2019-11-19 |
Family
ID=43500473
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014002480A MY172245A (en) | 2009-07-31 | 2010-07-28 | Subcutaneous anti-her2 antibody formulation |
| MYPI2012000396A MY163001A (en) | 2009-07-31 | 2010-07-28 | Subcutaneous anti-her2 antibody formulation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2012000396A MY163001A (en) | 2009-07-31 | 2010-07-28 | Subcutaneous anti-her2 antibody formulation |
Country Status (41)
Families Citing this family (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| MY152164A (en) | 2005-02-23 | 2014-08-15 | Genentech Inc | Extending time to disease progression or survival in cancer patients |
| SI2132573T1 (sl) | 2007-03-02 | 2014-07-31 | Genentech, Inc. | Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3 |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| EP3404044A1 (en) * | 2009-07-24 | 2018-11-21 | F. Hoffmann-La Roche AG | Optimizing the production of antibodies |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| US20110158987A1 (en) * | 2009-12-29 | 2011-06-30 | F. Hoffmann-Laroche Ag | Novel antibody formulation |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| KR102679155B1 (ko) | 2011-10-14 | 2024-06-28 | 제넨테크, 인크. | Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품 |
| DK2773671T3 (da) | 2011-11-04 | 2021-11-15 | Zymeworks Inc | Udformning af stabilt heterodimert antistof med mutationer i fc-domænet |
| AR090244A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Formulacion de anticuerpo anti-selectina p |
| US9574193B2 (en) | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
| WO2013173789A2 (en) | 2012-05-17 | 2013-11-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
| US20130309226A1 (en) | 2012-05-18 | 2013-11-21 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
| PT2864346T (pt) | 2012-06-21 | 2018-12-12 | Synthon Biopharmaceuticals Bv | Método de purificação de um anticorpo |
| US9777067B2 (en) | 2012-09-27 | 2017-10-03 | Massachusetts Institute Of Technology | HER2- and VEGF-A-binding proteins with enhanced stability |
| KR101454646B1 (ko) * | 2012-11-05 | 2014-10-27 | (주)한국비엠아이 | 히알루로니다아제의 안정화 제제 및 이를 포함하는 액상제제 |
| US20150343058A1 (en) * | 2012-12-21 | 2015-12-03 | Glenmark Pharmaceuticals S.A. | Antibody formulation |
| EP2968553B1 (en) * | 2013-03-13 | 2020-08-12 | F.Hoffmann-La Roche Ag | Antibody formulations |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| RU2737727C2 (ru) | 2013-04-16 | 2020-12-02 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| ES2833599T3 (es) * | 2014-02-28 | 2021-06-15 | Merus Nv | Anticuerpo que se une a ERBB-2 y ERBB-3 |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| CN104906576B (zh) * | 2014-03-13 | 2018-06-19 | 四川科伦博泰生物医药股份有限公司 | 可供皮下注射的高浓度抗vegf抗体配制剂 |
| WO2015164665A1 (en) | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| CN106573955B (zh) | 2014-06-23 | 2021-02-26 | 诺华股份有限公司 | 位点特异性蛋白质修饰 |
| EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| EP3193932B1 (en) | 2014-09-15 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibody formulations |
| US10793630B2 (en) | 2014-12-04 | 2020-10-06 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute myeloid leukemia |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| AU2016209968B2 (en) | 2015-01-23 | 2018-11-29 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| US9824394B1 (en) | 2015-02-06 | 2017-11-21 | Square, Inc. | Payment processor financing of customer purchases |
| US9779432B1 (en) | 2015-03-31 | 2017-10-03 | Square, Inc. | Invoice financing and repayment |
| KR102602754B1 (ko) | 2015-05-20 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체 |
| HRP20241134T1 (hr) | 2015-05-30 | 2024-11-22 | F. Hoffmann-La Roche Ag | Metode liječenja her2-pozitivnog prethodno neliječenog metastatskog raka dojke |
| PE20181323A1 (es) * | 2015-06-22 | 2018-08-14 | Janssen Biotech Inc | Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina |
| WO2017003270A1 (ko) * | 2015-07-02 | 2017-01-05 | 주식회사 녹십자 | 헌터증후군 치료제 및 치료방법 |
| KR20170004814A (ko) * | 2015-07-02 | 2017-01-11 | 주식회사 녹십자 | 헌터증후군 치료제 |
| KR20180054791A (ko) * | 2015-09-28 | 2018-05-24 | 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 | 안정한 항-pd-1 항체 약학적 제조물 및 의료에서의 그의 적용 |
| SG11201803359VA (en) | 2015-10-23 | 2018-05-30 | Merus Nv | Binding molecules that inhibit cancer growth |
| BR112018008901A8 (pt) * | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | formulações subcutâneas de anticorpos anti-cd 38 e seus usos |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| JP6946304B2 (ja) | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| PL3479819T3 (pl) | 2016-06-30 | 2024-07-01 | Celltrion Inc. | Stabilny ciekły preparat farmaceutyczny |
| EP4050034B1 (en) | 2016-09-14 | 2024-05-08 | TeneoOne, Inc. | Cd3 binding antibodies |
| CA3041350A1 (en) * | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Subcutaneous delivery of messenger rna |
| KR102633423B1 (ko) | 2016-12-21 | 2024-02-06 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| TW201827077A (zh) | 2016-12-28 | 2018-08-01 | 美商建南德克公司 | 晚期her2表現癌症之治療 |
| KR20200113292A (ko) * | 2017-01-17 | 2020-10-06 | 제넨테크, 인크. | 피하 her2 항체 제형 |
| SI3589661T1 (sl) | 2017-03-02 | 2024-03-29 | Genentech, Inc. | Adjuvansno zdravljenje her2 pozitivnega raka dojke |
| JP7737220B2 (ja) | 2017-03-31 | 2025-09-10 | メルス ナムローゼ フェンノートシャップ | ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体 |
| WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
| CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| WO2018211517A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| JP2020521788A (ja) * | 2017-06-02 | 2020-07-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 免疫アゴニストの投与経路 |
| CA3067584A1 (en) | 2017-06-20 | 2018-12-27 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| AU2018287514B2 (en) * | 2017-06-23 | 2024-05-23 | Rab Diagnostics As | Diagnosis and treatment of cancer |
| WO2019020745A1 (en) * | 2017-07-28 | 2019-01-31 | F. Hoffmann-La Roche Ag | Bispecific antibody formulation |
| DK3665198T3 (da) | 2017-08-09 | 2025-04-28 | Merus Nv | Antistoffer, der binder egfr og cmet |
| JP2020533362A (ja) | 2017-09-13 | 2020-11-19 | テネオバイオ， インコーポレイテッド | エクト酵素に結合する重鎖抗体 |
| PT3681483T (pt) * | 2017-09-15 | 2022-08-22 | Amgen Inc | Processo para formulação farmacêutica liofilizada de uma proteína terapêutica |
| WO2019089832A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| ES2983433T3 (es) | 2017-12-22 | 2024-10-23 | Novartis Ag | Tratamiento de trastornos metabólicos con variantes de FGF21 |
| EP3728319A1 (en) | 2017-12-22 | 2020-10-28 | TeneoBio, Inc. | Heavy chain antibodies binding to cd22 |
| CN107898756B (zh) * | 2017-12-22 | 2020-11-20 | 东曜药业有限公司 | 一种用于皮下或肌肉注射的高浓度尼妥珠单抗制剂及其制备方法和应用 |
| CN112165951B (zh) * | 2018-04-16 | 2024-12-13 | 默克专利股份有限公司 | 用于改善热稳定性的蛋白质制剂添加剂 |
| EP3560945A1 (en) | 2018-04-27 | 2019-10-30 | F. Hoffmann-La Roche AG | Methods for purification of polypeptides using polysorbates |
| MX2020012286A (es) | 2018-05-16 | 2021-04-28 | Janssen Biotech Inc | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t. |
| CN110732023B (zh) * | 2018-07-18 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种her2抗体药物组合物及其用途 |
| US11730698B2 (en) | 2018-07-19 | 2023-08-22 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
| JP7439046B2 (ja) | 2018-07-20 | 2024-02-27 | テネオツー・インコーポレイテッド | Ｃｄ１９に結合する重鎖抗体 |
| CA3093885A1 (en) | 2018-07-25 | 2020-01-30 | Alteogen, Inc. | Novel hyaluronidase variants and pharmaceutical composition comprising the same |
| JP2022500414A (ja) | 2018-09-12 | 2022-01-04 | シルバーバック セラピューティックス インコーポレイテッド | 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物 |
| WO2020060183A1 (ko) * | 2018-09-18 | 2020-03-26 | 삼성바이오에피스 주식회사 | 트라스투주맙 항체 안정화 액체 제제 |
| WO2020087065A1 (en) | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| WO2020092546A1 (en) * | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions |
| US20210380694A1 (en) * | 2018-11-07 | 2021-12-09 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| CN111202845A (zh) * | 2018-11-22 | 2020-05-29 | 上海医药集团股份有限公司 | 包含抗cd20抗体的药物配制剂及其制备方法和应用 |
| EP3887393A1 (en) | 2018-11-26 | 2021-10-06 | Novartis AG | Lpl-gpihbp1 fusion polypeptides |
| US20220072167A1 (en) * | 2019-01-04 | 2022-03-10 | Actinium Pharmaceuticals, Inc. | Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody Radioconjugates |
| WO2020152367A1 (en) | 2019-01-25 | 2020-07-30 | Ospedale San Raffaele S.R.L. | Inhibitor of dux4 and uses thereof |
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
| SG11202110512WA (en) * | 2019-03-25 | 2021-10-28 | Alteogen Inc | Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection |
| KR20210149076A (ko) | 2019-04-05 | 2021-12-08 | 테네오바이오, 인코포레이티드 | Psma에 결합하는 중쇄 항체 |
| CN110179746A (zh) * | 2019-05-17 | 2019-08-30 | 通化东宝生物科技有限公司 | 一种稳定的苏金单抗注射剂及其制备方法 |
| BR112021024956A2 (pt) | 2019-06-14 | 2022-01-25 | Teneobio Inc | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 |
| US20220249685A1 (en) | 2019-06-19 | 2022-08-11 | Silverback Therapeutics, Inc. | Anti-mesothelin antibodies and immunoconjugates thereof |
| US20230374130A1 (en) | 2019-07-30 | 2023-11-23 | Qlsf Biotherapeutics, Inc. | Bispecific anti lrrc15 and cd3epsilon antibodies |
| KR20220044286A (ko) * | 2019-08-07 | 2022-04-07 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 항 pd-1/her2 이중특이성 항체를 포함하는 제제, 이의 제조 방법 및 용도 |
| GB201913697D0 (en) | 2019-09-23 | 2019-11-06 | King S College London | DAP10/DAP12 fusion polypeptides |
| WO2021079337A1 (en) * | 2019-10-23 | 2021-04-29 | Cadila Healthcare Limited | Pharmaceutical formulation of anti-her2 antibody and preparation thereof |
| KR20220115566A (ko) | 2019-11-15 | 2022-08-17 | 시아겐 인크. | 항-her2 항체-약물 접합체와 조합된 투카티닙으로 her2 양성 유방암을 치료하는 방법 |
| MX2022005317A (es) * | 2019-11-15 | 2022-05-26 | Hoffmann La Roche | Prevencion de formacion de particulas visibles en soluciones acuosas de proteina. |
| WO2021096278A1 (ko) * | 2019-11-15 | 2021-05-20 | 삼성바이오에피스 주식회사 | 항체 의약품용 액상 조성물 |
| AU2020399619A1 (en) * | 2019-12-09 | 2022-06-09 | Genentech, Inc. | Anti-PD-L1 antibody formulations |
| CU20190104A7 (es) | 2019-12-17 | 2021-08-06 | Ct Inmunologia Molecular | Formulación estable del anticuerpo nimotuzumab |
| JP2023507120A (ja) | 2019-12-18 | 2023-02-21 | テネオフォー， インコーポレイテッド | Ｃｄ３８に結合する重鎖抗体 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| CN115066262B (zh) * | 2020-03-04 | 2025-07-15 | 上海复宏汉霖生物技术股份有限公司 | 一种包含贝伐珠单抗的药物配制剂 |
| GB202003277D0 (en) | 2020-03-06 | 2020-04-22 | King S College London | Therapeutic agents |
| IL297644A (en) | 2020-04-29 | 2022-12-01 | Teneobio Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| CA3214992A1 (en) | 2020-04-29 | 2021-11-04 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| GB202007655D0 (en) | 2020-05-22 | 2020-07-08 | King S College London | Chimeric nkg2d protein |
| CN113797161A (zh) * | 2020-06-11 | 2021-12-17 | 上海宝济药业有限公司 | 一种重组人透明质酸酶的液体制剂及其应用 |
| CN113827717A (zh) * | 2020-06-23 | 2021-12-24 | 三生国健药业（上海）股份有限公司 | 抗her2单克隆抗体冻干制剂及制备方法 |
| CN113827718A (zh) * | 2020-06-24 | 2021-12-24 | 上海宝济药业有限公司 | 一种含有透明质酸酶的制剂及其应用 |
| JP2023532122A (ja) | 2020-06-29 | 2023-07-26 | ジェネンテック， インコーポレイテッド | ペルツズマブにトラスツズマブを加えた固定用量配合剤 |
| PE20230464A1 (es) | 2020-06-30 | 2023-03-14 | Teneobio Inc | Union de anticuerpos multiespecificos a bcma |
| CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
| JP7622088B2 (ja) | 2020-08-07 | 2025-01-27 | アルテオジェン・インコーポレイテッド | 組換えヒアルロニダーゼの生産方法 |
| JP2023545447A (ja) | 2020-10-16 | 2023-10-30 | キューエルエスエフ バイオセラピューティクス， インコーポレイテッド | Ｐｄ－ｌ１に結合する多重特異性結合化合物 |
| TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Pharmaceutical compositions of a her2/neu antibody and use of the same |
| KR20230129462A (ko) * | 2020-12-30 | 2023-09-08 | 상하이 바오 파마슈티컬스 컴퍼니 리미티드 | 재조합 인간 히알루로니다제 제제 및 이의 응용 |
| CN116964096A (zh) * | 2021-02-23 | 2023-10-27 | 江苏康宁杰瑞生物制药有限公司 | 预防、减轻或治疗肿瘤的方法 |
| CA3211138A1 (en) | 2021-02-25 | 2022-09-01 | Teneobio, Inc. | Anti-psma antibodies and car-t structures |
| KR20230150825A (ko) | 2021-02-26 | 2023-10-31 | 테네오바이오, 인코포레이티드 | 항-muc1-c 항체 및 car-t 구조 |
| WO2022200442A1 (en) | 2021-03-23 | 2022-09-29 | King's College London | Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| KR20230166090A (ko) | 2021-04-06 | 2023-12-06 | 테네오바이오, 인코포레이티드 | 항-cd19 항체 및 car-t 구조체 |
| IL306045A (en) | 2021-04-16 | 2023-11-01 | Teneobio Inc | Anti-cd20 antibodies and car-t structures |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
| WO2023019556A1 (zh) * | 2021-08-20 | 2023-02-23 | 齐鲁制药有限公司 | 一种高浓度抗her2的抗体制剂及其用途 |
| MX2024004550A (es) | 2021-10-14 | 2024-04-29 | Teneobio Inc | Proteinas de union a la mesotelina y usos de las mismas. |
| TWI864690B (zh) * | 2022-04-22 | 2024-12-01 | 台康生技股份有限公司 | 用於皮下投予之包含抗-her2抗體的藥學組合物 |
| WO2024026358A1 (en) | 2022-07-27 | 2024-02-01 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| GB202214120D0 (en) | 2022-09-27 | 2022-11-09 | King S College London | Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof |
| AU2023356984A1 (en) | 2022-10-05 | 2025-03-20 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
| WO2024178056A1 (en) | 2023-02-21 | 2024-08-29 | Teneobio, Inc. | C-kit binding proteins, chimeric antigen receptors, and uses thereof |
| WO2024220256A1 (en) | 2023-04-18 | 2024-10-24 | Qlsf Biotherapeutics, Inc. | Antibodies binding to ly6g6d |
| WO2025158306A1 (en) * | 2024-01-25 | 2025-07-31 | Intas Pharmaceuticals Ltd. | Novel high concentration phesgo formulation |
| WO2025168089A1 (zh) * | 2024-02-08 | 2025-08-14 | 上海宝济药业股份有限公司 | 用于皮下给药的药物组合及其应用 |
| WO2025196207A1 (en) | 2024-03-20 | 2025-09-25 | King's College London | Compositions and methods for use in depleting senescent cells and treating aging |
| WO2025217101A2 (en) | 2024-04-09 | 2025-10-16 | Amgen Inc. | Agonistic anti-il-2rbg heavy‑chain antibodies |
| WO2025235357A1 (en) | 2024-05-06 | 2025-11-13 | Rondo Therapeutics, Inc. | Bispecific antibodies that bind to cd28 and nectin-4 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US533A (en) | 1837-12-26 | Truss for hermta | ||
| US4943A (en) | 1847-01-26 | Harness-buckle | ||
| US2795529A (en) | 1954-06-17 | 1957-06-11 | American Home Prod | Stabilized hyaluronidase solution containing calcium chloride |
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0491675A1 (en) | 1984-01-30 | 1992-06-24 | Imperial Cancer Research Technology Limited | Improvements relating to growth factors |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| JP3208427B2 (ja) | 1989-09-29 | 2001-09-10 | オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド | ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量 |
| US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| US5721348A (en) | 1990-12-14 | 1998-02-24 | University Of Connecticut | DNA encoding PH-20 proteins |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
| AU687346B2 (en) | 1992-06-30 | 1998-02-26 | Oncologix, Inc. | A combination of anti-erbB-2 monoclonal antibodies and method of using |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| ATE176910T1 (de) | 1994-07-21 | 1999-03-15 | Akzo Nobel Nv | Zyklische keton peroxyde zubereitungen |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5573186A (en) | 1995-03-20 | 1996-11-12 | Moen Incorporated | Stationary venturi diverter valve |
| EP0817775B1 (en) | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| DK2275119T3 (da) * | 1995-07-27 | 2013-11-11 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| EP0892789B2 (en) | 1996-04-12 | 2009-11-18 | Warner-Lambert Company LLC | Irreversible inhibitors of tyrosine kinases |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| DK1308456T3 (da) | 1998-05-06 | 2007-12-27 | Genentech Inc | Antistofoprensning ved ionbytterkromatografi |
| NZ516830A (en) | 1999-06-25 | 2004-07-30 | Genentech Inc | Humanized anti-ErbB2 antibodies conjugated with a cytotoxic or chemotherapeutic agent for treating cancer |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| HU231064B1 (hu) | 1999-08-27 | 2020-03-30 | Genentech, Inc. | Anti-ErbB2 antitestek adagolási sémái és alkalmazásuk rákos betegségek kezelésére |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| CN1447696A (zh) | 2000-05-19 | 2003-10-08 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| EP1314437B1 (en) | 2000-08-11 | 2014-06-25 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
| DK2314686T4 (da) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Celler, der danner antistofsammensætninger |
| IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| DE10153197A1 (de) | 2001-10-27 | 2003-05-08 | Merck Patent Gmbh | Pigment mit Metallglanz |
| NZ534542A (en) | 2002-02-14 | 2006-08-31 | Chugai Pharmaceutical Co Ltd | Antibody-containing solutions in which the formation of degradation products and insoluble particles during storage and freeze/thaw cycles is inhibited by adding a sugar and surfactant respectively |
| TW555245U (en) | 2003-01-29 | 2003-09-21 | Hon Hai Prec Ind Co Ltd | Cable connector assembly |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US20090123367A1 (en) | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| PT1603541E (pt) | 2003-03-05 | 2010-02-19 | Halozyme Inc | Glicoproteína hialuronidase solúvel (shasegp), processo para preparação da mesma, suas utilizações e composições farmacêuticas que a compreendem. |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| WO2004091658A1 (en) | 2003-04-04 | 2004-10-28 | Genentech, Inc. | High concentration antibody and protein formulations |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| AU2004247015B2 (en) | 2003-05-14 | 2010-12-16 | Immunogen, Inc. | Drug conjugate composition |
| MXPA06002159A (es) | 2003-08-26 | 2006-05-22 | Becton Dickinson Co | Metodos para la administracion intradermica de agentes terapeuticos. |
| BRPI0415849A (pt) | 2003-10-24 | 2007-01-02 | Mdc Invest Holdings Inc | método para misturar uma mistura com uma seringa, e, seringas de misturar para misturar uma mistura e para misturar um fluido medicinal |
| BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
| DK1771482T3 (da) | 2004-07-22 | 2014-10-20 | Genentech Inc | HER2-antistofsammensætning |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| TWI441646B (zh) | 2005-01-21 | 2014-06-21 | Genentech Inc | 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途 |
| TW200638943A (en) | 2005-01-28 | 2006-11-16 | Wyeth Corp | Stabilized liquid polypeptide formulations |
| MY152164A (en) | 2005-02-23 | 2014-08-15 | Genentech Inc | Extending time to disease progression or survival in cancer patients |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2618482C (en) | 2005-08-19 | 2014-10-07 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
| EP1977763A4 (en) | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
| TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| EP1998806A1 (en) | 2006-03-28 | 2008-12-10 | F. Hoffmann-Roche AG | Anti-igf-1r human monoclonal antibody formulation |
| PE20090329A1 (es) | 2007-05-30 | 2009-03-27 | Abbott Lab | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos |
| JP5070993B2 (ja) | 2007-08-27 | 2012-11-14 | 富士通株式会社 | 音処理装置、位相差補正方法及びコンピュータプログラム |
| EP2212432A4 (en) * | 2007-10-22 | 2011-10-19 | Schering Corp | COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES |
| PL2234600T3 (pl) | 2007-12-21 | 2015-02-27 | Hoffmann La Roche | Preparat przeciwciała |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| TWI532498B (zh) * | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| ES2498741T3 (es) | 2008-09-10 | 2014-09-25 | F. Hoffmann-La Roche Ag | Dispositivo de administración para uso con un fármaco terapéutico |
| US7905299B2 (en) | 2008-09-18 | 2011-03-15 | Longyear Tm, Inc. | Articulation assembly for moving a drill mast |
| KR20110047232A (ko) | 2008-09-19 | 2011-05-06 | 에프. 호프만-라 로슈 아게 | 신규한 항체 제형 |
| US20100305500A1 (en) | 2009-05-29 | 2010-12-02 | Pacira Pharmaceuticals, Inc. | Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| SG178226A1 (en) | 2009-08-04 | 2012-03-29 | Genentech Inc | Concentrated polypeptide formulations with reduced viscosity |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| JP2013541594A (ja) | 2010-11-08 | 2013-11-14 | ジェネンテック， インコーポレイテッド | 皮下投与される抗ｉｌ−６受容体抗体 |
| KR102679155B1 (ko) | 2011-10-14 | 2024-06-28 | 제넨테크, 인크. | Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품 |
| RU2737727C2 (ru) | 2013-04-16 | 2020-12-02 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| KR20200113292A (ko) | 2017-01-17 | 2020-10-06 | 제넨테크, 인크. | 피하 her2 항체 제형 |
| SI3589661T1 (sl) | 2017-03-02 | 2024-03-29 | Genentech, Inc. | Adjuvansno zdravljenje her2 pozitivnega raka dojke |
| SG11202110512WA (en) | 2019-03-25 | 2021-10-28 | Alteogen Inc | Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection |
| JP2023532122A (ja) | 2020-06-29 | 2023-07-26 | ジェネンテック， インコーポレイテッド | ペルツズマブにトラスツズマブを加えた固定用量配合剤 |
| BR112023000707A2 (pt) | 2020-07-14 | 2023-01-31 | Hoffmann La Roche | Ensaio de ligação para uma combinação de dose fixa, proteína, kits, composições e métodos para avaliar uma composição de dose fixa, fazer uma composição e para analisar o teor de proteína de uma combinação de dose fixa |
| AU2023234511A1 (en) | 2022-03-14 | 2024-09-12 | F. Hoffmann-La Roche Ag | Combination therapies for breast cancer |
-
2010
- 2010-07-27 US US12/804,703 patent/US9345661B2/en active Active
- 2010-07-28 MY MYPI2014002480A patent/MY172245A/en unknown
- 2010-07-28 EP EP23172095.4A patent/EP4257150A3/en active Pending
- 2010-07-28 SI SI201030218T patent/SI2459167T2/sl unknown
- 2010-07-28 EP EP23206430.3A patent/EP4339212B1/en active Active
- 2010-07-28 IN IN961CHN2012 patent/IN2012CN00961A/en unknown
- 2010-07-28 RS RS20230476A patent/RS64314B1/sr unknown
- 2010-07-28 RS RS20130343A patent/RS52913B2/sr unknown
- 2010-07-28 JP JP2012522158A patent/JP5462944B2/ja active Active
- 2010-07-28 PE PE2012000105A patent/PE20120665A1/es active IP Right Grant
- 2010-07-28 SI SI201032130T patent/SI2687202T1/sl unknown
- 2010-07-28 PL PL10737891.1T patent/PL2459167T5/pl unknown
- 2010-07-28 MY MYPI2012000396A patent/MY163001A/en unknown
- 2010-07-28 NZ NZ597190A patent/NZ597190A/xx unknown
- 2010-07-28 EA EA201200204A patent/EA027553B1/ru active Protection Beyond IP Right Term
- 2010-07-28 HR HRP20230462TT patent/HRP20230462T1/hr unknown
- 2010-07-28 KR KR1020137008026A patent/KR101769652B1/ko active Active
- 2010-07-28 ES ES13166031T patent/ES2948033T3/es active Active
- 2010-07-28 EP EP13166031.8A patent/EP2687202B1/en active Active
- 2010-07-28 PT PT131660318T patent/PT2687202T/pt unknown
- 2010-07-28 PE PE2013000301A patent/PE20131324A1/es active IP Right Grant
- 2010-07-28 DK DK13166031.8T patent/DK2687202T3/da active
- 2010-07-28 CN CN202111089810.5A patent/CN113967194A/zh active Pending
- 2010-07-28 HR HRP20130697TT patent/HRP20130697T4/hr unknown
- 2010-07-28 MX MX2013009895A patent/MX355450B/es unknown
- 2010-07-28 CN CN201510673057.2A patent/CN105168125A/zh active Pending
- 2010-07-28 MX MX2012001124A patent/MX2012001124A/es active IP Right Grant
- 2010-07-28 CA CA2768458A patent/CA2768458C/en active Active
- 2010-07-28 LT LTEP13166031.8T patent/LT2687202T/lt unknown
- 2010-07-28 WO PCT/EP2010/060930 patent/WO2011012637A2/en not_active Ceased
- 2010-07-28 SG SG2012006748A patent/SG178185A1/en unknown
- 2010-07-28 MA MA34587A patent/MA33471B1/fr unknown
- 2010-07-28 FI FIEP13166031.8T patent/FI2687202T3/fi active
- 2010-07-28 PL PL13166031.8T patent/PL2687202T3/pl unknown
- 2010-07-28 DK DK23206430.3T patent/DK4339212T3/da active
- 2010-07-28 BR BR112012002080A patent/BR112012002080A2/pt not_active Application Discontinuation
- 2010-07-28 KR KR1020127005268A patent/KR101413947B1/ko active Active
- 2010-07-28 DK DK10737891.1T patent/DK2459167T3/da active
- 2010-07-28 SG SG2013056155A patent/SG193146A1/en unknown
- 2010-07-28 CN CN201080043414.2A patent/CN102573789B/zh active Active
- 2010-07-28 EA EA201400270A patent/EA031013B1/ru active Protection Beyond IP Right Term
- 2010-07-28 PT PT107378911T patent/PT2459167E/pt unknown
- 2010-07-28 ES ES10737891T patent/ES2413090T5/es active Active
- 2010-07-28 UA UAA201201888A patent/UA102166C2/ru unknown
- 2010-07-28 UA UAA201300938A patent/UA104254C2/ru unknown
- 2010-07-28 NZ NZ603900A patent/NZ603900A/en unknown
- 2010-07-28 AU AU2010277657A patent/AU2010277657B2/en active Active
- 2010-07-28 EP EP10737891.1A patent/EP2459167B2/en active Active
- 2010-07-28 HU HUE13166031A patent/HUE062122T2/hu unknown
- 2010-07-29 AR ARP100102752A patent/AR077605A1/es not_active Application Discontinuation
- 2010-07-30 TW TW099125487A patent/TWI401089B/zh active
- 2010-07-30 TW TW102110768A patent/TWI474834B/zh active
-
2011
- 2011-12-16 CR CR20110679A patent/CR20110679A/es unknown
- 2011-12-21 ZA ZA2011/09459A patent/ZA201109459B/en unknown
- 2011-12-26 CO CO11178794A patent/CO6430421A2/es not_active Application Discontinuation
-
2012
- 2012-01-05 IL IL217382A patent/IL217382A/en active IP Right Grant
- 2012-01-16 TN TNP2012000023A patent/TN2012000023A1/en unknown
- 2012-01-30 GT GT201200024A patent/GT201200024A/es unknown
- 2012-01-31 EC EC2012011643A patent/ECSP12011643A/es unknown
- 2012-01-31 CL CL2012000269A patent/CL2012000269A1/es unknown
- 2012-10-17 ZA ZA2012/07815A patent/ZA201207815B/en unknown
- 2012-11-02 HK HK16103046.0A patent/HK1215157A1/zh unknown
-
2013
- 2013-03-15 US US13/833,316 patent/US20130216532A1/en not_active Abandoned
- 2013-06-11 JP JP2013123231A patent/JP5878144B2/ja active Active
- 2013-07-22 CY CY20131100613T patent/CY1114185T1/el unknown
- 2013-09-05 CL CL2013002550A patent/CL2013002550A1/es unknown
-
2015
- 2015-10-06 DO DO2015000255A patent/DOP2015000255A/es unknown
-
2016
- 2016-02-25 US US15/053,217 patent/US9968676B2/en active Active
-
2017
- 2017-06-30 AR ARP170101828A patent/AR108936A2/es not_active Application Discontinuation
- 2017-08-10 IL IL253941A patent/IL253941B/en unknown
-
2018
- 2018-04-10 US US15/949,616 patent/US20180228895A1/en not_active Abandoned
-
2021
- 2021-07-27 US US17/443,780 patent/US20210353753A1/en not_active Abandoned
-
2023
- 2023-06-02 EC ECSENADI202341058A patent/ECSP23041058A/es unknown
- 2023-09-01 US US18/459,857 patent/US20240207400A1/en not_active Abandoned
-
2024
- 2024-04-15 US US18/635,280 patent/US20250090660A1/en active Pending
- 2024-12-20 US US18/991,315 patent/US12427193B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY172245A (en) | Subcutaneous anti-her2 antibody formulation | |
| PH12016501002A1 (en) | Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody | |
| AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| MY159156A (en) | Antibody formulation | |
| TH138064A (th) | สูตรตำรับแอนทิบอดีแอนทิ-her2 ใต้หนัง | |
| TH151334A (th) | สูตรผสมเชิงเภสัชกรรมที่เข้มข้นสูง, ซึ่งเสถียรของแอนติ-CD20 แอนติบอดี (anti-CD20 antibody) |